Abstract
Objectives To evaluate the frequency of antimicrobial-resistant bloodstream infections (AMR BSI) in Thailand
Methods We analyzed data from 2022, generated by 111 public hospitals in health regions 1 to 12, using the AutoMated tool for Antimicrobial resistance Surveillance System (AMASS) and submitted to the Ministry of Public Health, Thailand. Multilevel Poisson regression models were used.
Results The most common cause of community-origin AMR BSI was third-generation cephalosporin-resistant Escherichia coli (3GCREC, 65.6%; 5,101/7,773 patients) and of hospital-origin AMR BSI was carbapenem-resistant Acinetobacter baumannii (CRAB, 51.2%, 4,968/9,747 patients). The percentage of patients tested for BSI was negatively associated with the frequency of community-origin 3GCREC BSI and hospital-origin CRAB BSI. Hospitals in health regions 4 (lower central) had the highest frequency of community-origin 3GCREC BSI per 100,000 tested patients (adjusted incidence rate ratio, 2.06; 95% confidence interval: 1.52-2.97). Health regions were not associated with the frequency of hospital-origin CRAB BSI, although between-hospital variation was high even adjusting for hospital level and size.
Conclusion The high between-hospital variation of hospital-origin CRAB BSI suggests the importance of hospital-specific factors. Our approach and findings highlight health regions and hospitals where actions against AMR infection, including antimicrobial stewardship and infection control, should be prioritized.
Highlights
The frequency of AMR BSI in 111 public hospitals in Thailand in 2022 was studied.
The frequency of community-origin 3GCREC BSI was different by regions.
The frequency of hospital-origin CRAB BSI varied greatly among hospitals.
Underuse of BC was associated with the higher frequency of AMR BSI per tested patients.
Our findings contributed to actions against AMR at local and national levels.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is supported by Ministry of Public Health Thailand and Wellcome Trust of Great Britain (224681/Z/21/Z). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical permission for this study was obtained from the Institute for the Committee of the Faculty of Tropical Medicine, Mahidol University (TMEC 23-085). Individual patient consent was not sought as this was a retrospective study using summary data, and the Ethical and Scientific Review Committees approved the process.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The hospital-level summary data used for the study are open-access and available at https://figshare.com/s/6aee792c15290d7dea3c.
